Pfizer

This study looks at whether getting a second RSV vaccine during a later pregnancy is safe and how long protection lasts from a first dose. About 550 pregnant women who previously received the RSV vaccine will get another dose. Researchers will monitor side effects in mothers and …

This study tests an experimental vaccine designed to protect against E. coli bacteria. Researchers are giving the vaccine to 310 healthy adults aged 18 to 64 to see if it is safe and tolerable. The main goal is to check for side effects like injection site pain, fever, or fatigue…

This study tests whether a fifth dose of Pfizer's Lyme disease vaccine (VLA15) is safe and boosts immunity. Healthy people aged 7 and older who already received four doses will get either the vaccine or a placebo. Researchers will monitor side effects and immune responses over 12…

This study tests a vaccine given to pregnant women to protect their babies from group B streptococcus (GBS), a bacteria that can cause serious illness in newborns. About 6,000 healthy pregnant women will receive either the vaccine or a placebo (saltwater shot). Researchers will m…

This study tests whether a vaccine can prevent C. difficile infection, a serious gut infection often linked to antibiotic use. About 32,000 adults aged 65 and older will receive either the vaccine or a placebo shot. Researchers will track how many people get C. diff diarrhea over…

This study checks the safety of the Prevenar 20 vaccine after it is already available in Korea. About 660 people aged 6 weeks and older who are prescribed the vaccine will take part. Researchers will track any side effects for 28 days after vaccination.

This study looks at how well a 20-valent pneumococcal vaccine works against pneumonia in adults aged 65 and older. Participants are hospitalized with suspected pneumonia and provide a urine sample to check for specific bacterial strains. Researchers compare vaccination rates betw…

This study tests an experimental mRNA flu vaccine in healthy adults aged 18 and older. Researchers want to see if it is safe and triggers a strong immune response. Participants receive one shot and are followed for about 6 months with blood tests and a nasal swab. The results wil…

This study tracks 90 adults in France with untreated ALK-positive non-small cell lung cancer to see how effective and safe lorlatinib is in everyday medical practice. Researchers will measure how long patients live without the cancer growing and overall survival. The goal is to u…

This study tests an experimental drug called PF-07275315 in adults aged 35 to 80 with moderate-to-severe COPD who have had at least two flare-ups in the past year. Participants receive either the drug or a placebo as multiple shots over 24 or 52 weeks. The goal is to see if the d…

This study is checking how safe and effective the drug Cibinqo (abrocitinib) is for people with moderate to severe atopic dermatitis, a type of eczema. About 1,100 participants in Korea will take the tablet by mouth and be followed for one year. Researchers will track side effect…

This early-stage study tests a new medicine, PF-08046033, in adults with advanced lung, esophageal, or skin cancer that has spread or can't be removed. The main goals are to check safety, find the right dose, and see if it helps control the cancer. Participants receive the drug i…

This study watches adults in Korea with newly diagnosed acute myeloid leukemia (AML) who are receiving the drug Mylotarg. Researchers will track side effects and how the disease responds to treatment. The goal is to better understand the drug's safety and effectiveness in real-wo…

This study looks at the long-term safety and effects of an experimental medicine called PF-07868489 for people with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lung arteries makes the heart work harder. It is an open-label extension study, …

This study tests an experimental pill called ibuzatrelvir in adults and teens with COVID-19 who are not hospitalized but have a high risk of becoming severely ill. About 2,330 participants will receive either the pill or a placebo for 5 days, and researchers will track who needs …

This study follows 850 people with alopecia areata who are taking the medication ritlecitinib. Researchers want to see how much hair regrows over 24 weeks and how patients feel during treatment. The goal is to understand how well the drug works outside of a controlled clinical tr…

This study tests whether the experimental medicine abrocitinib can safely improve moderate-to-severe eczema in children aged 6 to 12. About 150 children will be randomly assigned to receive either the drug or a placebo for 16 weeks. The goal is to see if the medicine clears the s…

This study tests whether a targeted drug called inotuzumab ozogamicin works better than standard chemotherapy for children aged 1 to 17 with a first relapse of high-risk B-cell acute lymphoblastic leukemia. About 100 participants will receive either the new drug or standard thera…

This early-stage study tests a new drug called PF-08046876 in people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. The drug is designed to stick to cancer cells and kill them directly. The main goals are to check safety, find the best dose, an…

This study looks at the long-term safety and effectiveness of a medicine called marstacimab for people with severe hemophilia A or B. It is given as a shot under the skin to help prevent bleeding episodes. The study includes about 245 participants who have already completed earli…

This study looks at the long-term safety and effectiveness of a medicine called dazukibart for people with dermatomyositis or polymyositis, which are rare diseases that cause muscle weakness and inflammation. About 211 adults who were in a previous dazukibart study will receive t…

This study tests a new medicine called marstacimab in people with severe hemophilia A who have been on another medicine (emicizumab) for at least 6 months. The goal is to see if switching to marstacimab is safe and how it works in the body. About 15 teens and adults aged 12 to 75…

This study tests an oral medication called etrasimod in children aged 2 to 12 with moderate to severe ulcerative colitis. The goal is to see if it can safely reduce inflammation and bring about remission over 52 weeks. Participants who finish may continue treatment for up to 5 ye…

This study is testing a combination of two medicines, aztreonam and avibactam (ATM-AVI), to treat serious bacterial infections in newborns and infants up to 9 months old. The goal is to see how safe the drug is and how the body processes it. The study has two parts: first, a sing…

This study tests a daily pill called ritlecitinib for people with moderate to severe hidradenitis suppurativa (HS), a condition causing painful red skin lumps. About 240 adults who haven't been helped by antibiotics will receive either the drug or a placebo for 16 weeks. Research…

This study compares a new experimental drug (PF-08046054) to standard chemotherapy (docetaxel) in about 680 adults with advanced PD-L1 positive non-small cell lung cancer that has worsened after prior treatments. Participants are randomly assigned to receive either the new drug o…

This study tests an experimental drug called PF-07248144 in people with advanced breast, prostate, or lung cancer that has spread and no longer responds to standard treatments. The goal is to see if the drug is safe and can shrink or control tumors. About 320 participants will re…

This study looks at how safe and effective the drug BOSULIF is for people with chronic myeloid leukemia (CML) when used in normal medical practice. About 600 participants in Korea who are already taking or will start BOSULIF will be followed by their doctors. The goal is to track…

This study follows 360 adults aged 18-65 with moderate to severe ulcerative colitis who are prescribed etrasimod as part of their normal care. Researchers will track symptom changes—like stool frequency and rectal bleeding—over 52 weeks using health questionnaires completed onlin…

This study tests a new medicine called PF-08634404 combined with chemotherapy for adults with extensive-stage small cell lung cancer, a fast-spreading cancer. About 550 people who haven't had prior treatment for this stage will join. The goal is to see if the new combo works bett…

This early-stage study tests two drugs—elranatamab (a shot under the skin) and iberdomide (a pill)—in people whose multiple myeloma has returned or stopped responding to treatment. The goal is to find a safe dose and see how well the combination works. About 87 adults with myelom…

This study tests an oral medication called etrasimod in adolescents aged 12 to 17 with moderate-to-severe ulcerative colitis, a chronic gut condition. The goal is to see if the drug can safely reduce inflammation and bring the disease under control over 52 weeks. Participants who…

This study tests a new medicine, PF-08634404, for adults with advanced kidney cancer that has spread. The goal is to see if the drug, given alone or with other cancer treatments, can shrink tumors and is safe. Participants must not have had prior treatment for their advanced canc…

This study tests a new medicine called marstacimab in children aged 1 to 17 with severe hemophilia A or B. The goal is to see if a weekly shot under the skin can prevent bleeding episodes better than their past standard treatments. Participants receive the drug for 12 months, and…

This early-phase study tests a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors (like melanoma, lung, or colon cancer) that have a specific BRAF gene change and have stopped responding to standard treatments. The drug is given alone or combined w…

This study looks at how well the drug abrocitinib works for people with moderate-to-severe eczema (atopic dermatitis) who have already tried and not responded to, or couldn't tolerate, up to two other biologic treatments. Researchers will track 150 participants across the U.S. to…

This study follows 3,000 people in Korea with severe alopecia areata who are starting Litfulo. Researchers will track side effects and how well the drug regrows hair over 48 weeks. The goal is to confirm safety and effectiveness in real-world use.

This study tests whether a new drug called elranatamab, when combined with two standard drugs (daratumumab and lenalidomide), works better than the usual four-drug combination for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The st…

This study tests a new medicine called PF-08634404 combined with other cancer drugs in people with advanced non-small cell lung cancer that has spread and cannot be removed by surgery. The goal is to see if the combination is safe and can shrink tumors. About 162 adults will rece…

This study monitors the safety and effectiveness of Xeljanz in children aged 2 to 17 with active juvenile idiopathic arthritis or juvenile psoriatic arthritis. It is a post-marketing surveillance required by Korean regulators, following children for up to 44 weeks in routine care…

This study looks at the long-term safety and effects of a daily pill called ritlecitinib for people with severe alopecia areata, a condition causing major hair loss. Participants who completed earlier studies can join and will take the medicine for up to 3 years. The goal is to s…

This study gives people with solid tumors continued access to the drugs encorafenib and/or binimetinib if they were already benefiting from them in an earlier study. Participants will receive the same dose for up to about 5 years, while doctors monitor safety. Only those currentl…

This study tests whether adding a new drug (Sigvotatug Vedotin) to standard immunotherapy (pembrolizumab) helps people with advanced non-small cell lung cancer that has high PD-L1 levels live longer or delay cancer growth. About 714 participants will receive either the combo or p…

This study tests an experimental medicine called PF-07275315 for adults with moderate-to-severe asthma that is not well controlled. Participants will receive either the study drug or a placebo as injections over 12 weeks. The goal is to see if the drug improves lung function and …

This study tests a new medicine called elranatamab, given as a weekly shot, against standard drug combinations for multiple myeloma that has returned or not responded to prior treatments. About 492 adults whose cancer progressed after anti-CD38 therapy will take part. The goal is…

This study follows 120 people with ulcerative colitis in Sweden who are already prescribed tofacitinib as part of their routine care. Researchers will use registry data to see how many achieve remission and how well they stick with the treatment. The goal is to understand how the…

This early-stage study tests an experimental drug called mevrometostat in adults with advanced prostate cancer, small cell lung cancer, or follicular lymphoma that has stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink…

This study tests a new medicine called dazukibart (PF-06823859) for people with active dermatomyositis or polymyositis, rare diseases that cause muscle inflammation, weakness, and sometimes skin rash. About 318 adults will receive either the drug or a placebo as an IV infusion ev…

This study tests a new drug (PF-07220060) plus letrozole against standard treatments for a common type of advanced breast cancer (HR-positive, HER2-negative). About 1,020 adults who have not had prior treatment for their advanced disease will be randomly assigned to either the ne…

This study follows people with hemophilia A or B who already received a one-time gene therapy (giroctocogene fitelparvovec or fidanacogene elaparvovec) in earlier Pfizer trials. Researchers will monitor long-term safety, including blood clots, liver issues, and inhibitor developm…

This observational study follows 300 adults with moderate to severe ulcerative colitis who are prescribed etrasimod as part of their routine care. Researchers will track symptoms like stool frequency and rectal bleeding over 52 weeks to see how well the drug works in real life. P…

This study tests a medicine called disitamab vedotin in people with advanced breast cancer that has spread and is hard to treat. Participants must have tumors with a protein called HER2 and have had prior treatment. Everyone receives the drug through a vein every two weeks to see…

This study tests whether a new drug called ibuzatrelvir, alone or combined with remdesivir, works better than remdesivir alone for treating COVID-19 in adults with severely weakened immune systems. About 300 participants who have mild to moderate symptoms will be followed to see …

This study tests a new medicine, PF-08634404, for adults with advanced bladder cancer that has spread. Some participants get the drug alone, others get it with another cancer drug. The goal is to see if the treatment is safe and shrinks tumors. About 132 people will take part.

This study tests a new medicine called MET097, given as a weekly shot under the skin, to help adults with overweight or obesity and type 2 diabetes lose weight. About 1,000 people will take part for 21 months, with some receiving the study drug and others a placebo. The goal is t…

This study tests a daily pill called ritlecitinib for children aged 6 to 12 with severe alopecia areata, a condition causing significant hair loss. About 225 kids will receive either a high dose, low dose, or placebo for 6 months. The goal is to see if the medicine can safely reg…

This study tests a new medicine (PF-08634404) given with chemotherapy, then alone, for adults with transformed small cell lung cancer (T-SCLC), a rare and aggressive cancer. About 40 participants who have not yet been treated for T-SCLC will receive the drugs through IV infusions…

This study tests if adding an experimental drug (PF-06821497) to a standard treatment (enzalutamide) works better than the standard alone for men with a type of advanced prostate cancer that no longer responds to hormone therapy. About 900 participants will be randomly assigned t…

This study tests a new oral drug (PF-07248144) combined with fulvestrant in 400 people with advanced HR-positive, HER2-negative breast cancer that worsened after prior CDK4/6 inhibitor treatment. Half receive the new combo; the other half get standard care (everolimus plus endocr…

This early-stage study tests a new drug, PF-08052667, for adults with a type of bladder cancer that hasn't spread into the bladder muscle but is likely to return. The drug is given alone or with standard treatments like BCG and/or sasanlimab. The goal is to check safety and find …

This study tests whether taking rimegepant around the time of your period can prevent menstrual migraines. About 723 women with regular cycles and a history of menstrual migraines will receive either rimegepant or a placebo during the perimenstrual period. The goal is to see if t…

This study is tracking 183 adults with moderate-to-severe eczema (atopic dermatitis) who take abrocitinib pills daily for up to 24 months. Researchers want to see how well the drug clears or nearly clears the skin in real-life conditions, not just in a lab. Participants can also …

This study tests a new experimental drug, PF-07934040, for people with advanced solid tumors that have a KRAS gene mutation. The drug is taken as a pill twice a day, either alone or with other anti-cancer medicines given by IV. The goal is to find the safest dose and see if the d…

This study tests a new medicine called PF-08634404, given alone or with another drug (ipilimumab), for adults with advanced liver cancer that cannot be removed by surgery. The goal is to check safety and see if the treatment shrinks tumors. About 138 participants will receive the…

This study tests a new medicine, PF-08634404, combined with chemotherapy against the standard treatment (bevacizumab plus chemotherapy) in people with colorectal cancer that has spread. About 800 adults who have not had prior treatment for metastatic disease will be randomly assi…

This program offers early access to the drug etrasimod for people with ulcerative colitis who have not improved with at least three other treatments. It is designed for individual patients with no other options. The goal is to help control the disease when standard therapies have…

This study tests a new cancer pill (PF-08032562) in people with advanced breast or colorectal cancer that has spread. The goal is to find the safest dose and see how well it works alone or with other treatments. About 260 adults will take the pill daily in 28-day cycles, with som…

This study tests a new medicine (PF-08634404) combined with chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. The trial has two parts: first checking safety and response, then comparing the new combo t…

This program offers early access to ritlecitinib, an experimental pill, for people with severe alopecia areata who have lost at least half of their scalp hair and have not improved with standard treatments. The goal is to provide a potential treatment option before the drug is fu…

This study tests whether a new drug, PF-08634404, combined with chemotherapy works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned to receive either the n…

This study is tracking the safety and effectiveness of the arthritis drug Xeljanz XR in about 200 people in Korea who have moderate to severe rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Participants take the drug as part of their normal care, and researc…

This study tests a new IV antibiotic (aztreonam-avibactam) in hospitalized children aged 9 months to 18 years with serious gram-negative bacterial infections. The goal is to see how the drug moves through the body, if it is safe, and how well it works compared to the best availab…

This study tests a new drug called elranatamab, alone or with another drug (daratumumab), in people whose multiple myeloma has returned after at least one prior treatment. About 944 participants will be randomly assigned to one of three treatment groups. The goal is to see if elr…

This study tests if adding the experimental drug mevrometostat to standard enzalutamide therapy works better than enzalutamide alone for men with metastatic castration-sensitive prostate cancer (cancer that has spread but still responds to hormone therapy). About 1,000 participan…

This study tests a new experimental drug (PF-07799544) combined with another drug (PF-07799933) in adults with advanced solid tumors that have a specific gene change called BRAF V600. The goal is to see if the combination is safe and can shrink or control the cancer. Participants…

This study tests the long-term safety and effectiveness of a daily liquid medicine called abrocitinib for children aged 2 and older with moderate-to-severe eczema. About 500 kids will take the drug for up to 24 months, with or without topical creams. The goal is to see if the dru…

This study tests an experimental drug called PF-06835375 in adults with moderate to severe primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The drug is given as multiple injections under the skin. The main goal…

This study tests two experimental drugs (PF-07275315 and PF-07264660) for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to skin creams. About 340 participants will receive the drugs or a placebo as injections over several months. The goal is…

This study follows 200 people aged 12 and older with moderate-to-severe eczema who are starting a new prescription of abrocitinib. Researchers will track how well the drug controls symptoms like itching and rash over 12 months in real-world settings. The goal is to see if the imp…

This study offers ongoing access to the drug elranatamab for people with multiple myeloma who were already benefiting from it in earlier Pfizer studies. About 80 participants will continue treatment and be monitored for side effects. The goal is to keep providing the drug while c…

This study is testing a new oral medication called osivelotor for people with sickle cell disease. The main goals are to see if the drug can safely increase hemoglobin levels and reduce the frequency of painful vaso-occlusive crises (VOCs). The trial will involve nearly 400 adult…

This study tests whether the drug rimegepant can prevent migraines in children and adolescents aged 6 to 17 who have frequent migraines. Participants will receive either the drug or a placebo for 12 weeks to see if it reduces the number of migraine days per month. The goal is to …

This study tests a dissolving tablet called rimegepant to prevent migraines in adolescents aged 12 to 17 who have chronic migraine (15+ headache days per month). About 200 teens will take either rimegepant or a placebo every other day for 3 months, then all will receive rimegepan…

This early-stage study tests a new drug, PF-07832837, in healthy volunteers and people with moderate-to-severe atopic dermatitis (eczema). The main goal is to check safety and how the body processes the drug. Researchers will also look for early signs that it might improve eczema…

This study looks at possible eye-related side effects in people with cervical cancer that has returned or spread, who are being treated with the drug TIVDAK. About 100 participants will receive TIVDAK every three weeks and undergo regular eye exams before, during, and after treat…

This study tests if adding ponsegromab to standard chemotherapy can help adults with advanced pancreatic cancer who are losing weight and have poor appetite (cachexia). About 982 participants will receive either ponsegromab or a placebo alongside their first chemo treatment. The …

This study is checking how safe a migraine medicine called rimegepant is for children and teenagers aged 6 to 18 when used over a long period. About 600 participants who have migraines will take the medicine as needed for acute attacks. The main goal is to track any side effects …

This study tests the safety of a single dose of zavegepant nasal spray in 16 children aged 6 to 12 who have had migraines for at least 6 months. The medicine is given as one spray into one nostril, and the dose depends on the child's weight. Researchers will monitor how the body …

This study tests whether the drug rimegepant can safely and effectively stop moderate to severe migraine headaches in children and adolescents aged 6 to 17. About 2,100 participants will receive either the drug or a placebo. The goal is to see if the drug helps them become pain-f…

This study tests a daily oral medication called ritlecitinib for adults with chronic spontaneous urticaria (CSU) — a condition causing itchy hives and deep skin swelling without a clear trigger. About 200 participants who haven't found relief from antihistamines will be randomly …

This study tests an experimental oral medicine (PF-07328948) in 620 adults with heart failure. Participants will be randomly assigned to receive the drug or a placebo for 36 weeks. The goal is to see if the drug improves walking distance, heart failure symptoms, and quality of li…

This study looks at how an experimental medicine, PF-08653944, is handled by the body in adults with normal liver function and those with mild to severe liver problems. Participants receive a single injection and undergo blood tests and checkups. The goal is to gather safety and …

This study follows 780 pregnant women with migraine to see if taking the drug rimegepant affects pregnancy or baby health. Some women take the drug, others do not. Researchers track birth defects, pregnancy complications, and infant health up to 12 months after birth.

This study looks at how the experimental drug PF-07328948 is absorbed, distributed, and removed from the body in healthy men aged 18 to 64. Participants will take the drug by mouth and by injection, and provide blood, urine, and stool samples. The goal is to understand the drug's…

This study looks at health insurance records from Germany to learn more about a rare heart condition called ATTR-CM. Researchers will track survival rates, hospital visits, and how common the disease is. No new treatments or tests are given—just analysis of existing data to bette…

This study looks at how much of the medication etrasimod ends up in breast milk. About 8 healthy breastfeeding women will take a daily 2 mg dose for 7 days while staying at a clinic. They cannot breastfeed during the study, so they need an alternative feeding plan. The results wi…

This early-stage study tests a new medicine, PF-07985631, in healthy adults to see if it is safe and how the body handles it. The medicine is being developed for a kidney disease called IgA nephropathy. Participants receive either the drug or a placebo as an injection or IV, and …

This study looks at how the drug vepdegestrant is processed by the body in people with moderate to severe liver problems compared to healthy people. About 24 adults (ages 18-70) will take a single dose and stay at the clinic for 11 days. The goal is to understand how liver functi…

This study tests two different injector pens that deliver the same medicine (Genotropin) under the skin. Healthy adults aged 18-60 will receive one dose with each pen and have blood samples taken to compare how much medicine gets into the blood. The goal is to see if the pens wor…

This study watches pregnant women with eczema who take the drug CIBINQO and compares them to those who don't, to see if the drug affects the baby. About 400 women will join, and their babies will be followed for 12 months after birth. No extra treatments are given—just routine ca…

This study tracks the safety and effectiveness of Zavicefta, an antibiotic already approved in Korea, in 600 patients with serious abdominal, urinary tract, or hospital-acquired lung infections. Researchers will record any side effects and how well the drug works. The goal is to …

This study is checking the safety of a medicine called Somatrogon for children with growth hormone deficiency (short stature) in India. About 50 children aged 3 and older who are already prescribed Somatrogon will be followed for up to 3 years. Doctors will record any side effect…

This study looks at how different levels of liver function affect the way the body processes a new medicine called PF-07328948. Researchers will give a single tablet to 26 adults, some with liver problems and some healthy, and monitor them for about 6 days. The goal is to learn i…

This early-stage study in 16 healthy adults aims to compare how well a new tablet form of the experimental drug PF-07799933 is absorbed versus the current form. It also checks if a high-fat meal or an acid-reducing drug changes absorption. Participants take a single dose of the d…

This study tracks 600 adults with ALK-positive metastatic non-small cell lung cancer who are taking Lorviqua as part of their normal care in Korea. Researchers will record any side effects and measure how well the drug controls the cancer. The goal is to see how the drug performs…

This study looks at how the body handles a single dose of the experimental drug PF-07328948 in adults with normal or reduced kidney function. About 28 participants aged 18 to 80 will take one tablet and stay at a clinic for 6 days for monitoring. The goal is to understand safety …

This early-stage study tests how the body processes different doses of the experimental drug atirmociclib when taken with food. It involves 72 healthy adults aged 18-65. The goal is to measure drug levels in the blood and check safety, not to treat any disease.

This early-stage study tests a medicine called PF-08653944 in 20 adults who are overweight or have obesity. The goal is to see how it changes the speed at which the stomach empties food after a meal. Researchers will also check for side effects. The results will help plan future …

This study checks if a new tablet form of the drug tafamidis works the same as the current capsule in healthy adults. About 24 participants will take a single dose of each form under fed conditions. The goal is to measure drug levels in the blood, not to treat any disease.

This study follows 300 people under 21 who developed heart inflammation (myocarditis or pericarditis) within a week of receiving the COMIRNATY COVID-19 vaccine. Researchers will track their heart health for up to 5 years using imaging and tests to understand long-term effects. Th…

This early-stage study tests a new medicine, PF-07985631, in healthy adults to see if it is safe and how the body processes it. The drug is being developed for a kidney disease called IgA nephropathy. Participants receive either the drug or a placebo as a single injection and are…

This early-stage study tests a new tablet form of the experimental COVID-19 drug ibuzatrelvir in 18 healthy adults. Researchers want to see how much of the drug gets into the blood with the new tablet compared to the original, and whether taking it with food or as a drink changes…

This early-stage study is testing a single dose of an experimental medicine called PF-08653944 in 54 overweight or obese adults. The goal is to see how the drug is absorbed when injected into the thigh, upper arm, or abdomen. Researchers will also monitor safety through blood tes…

This study looks at how patients with metastatic breast cancer in Sweden are actually using the drug palbociclib in everyday medical practice. Researchers will track 1,500 adults who have filled a prescription for palbociclib to see how long they stay on treatment and how well th…